In brief, ATR inhibitors have preliminary clinical activity and are able to improve the survival benefit of patients with refractory solid tumors to some degree, which may make them competitive candidates for the treatment of recurrent endometrial cancer (regardless of P53 status). Here, TP53 is linked to endometrial cancer.